Lung cancer patients may get clot protection from common blood thinner
NCT ID NCT07160686
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 28 times
Summary
This study tests whether a daily blood thinner pill called apixaban can reduce the risk of blood clots in people with lung cancer who are receiving chemotherapy or similar treatments. About 1,456 participants will take either apixaban or a placebo for six months alongside their cancer therapy. The goal is to see if the drug safely prevents clots without causing serious bleeding.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THROMBOPROPHYLAXIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
University of Birmingham
Birmingham, B15 2TT, United Kingdom
Conditions
Explore the condition pages connected to this study.